GlassScriptPhysician profile
Andrea Holzman
NPI 1760903173
$4,730.39
in general payments reported to CMS, 2019-2025
28 companies · $1,097 in 2025
The $1,097 reported for 2025 was more than what 88% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $558 · 2022: $691 · 2023: $989 · 2024: $1,395 · 2025: $1,097.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,481.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,481.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $720.57 | 2021-2025 | Breztri, Airsupra, Farxiga |
| Sanofi-Aventis U.S. LLC | $572.11 | 2021-2023 | |
| Novo Nordisk INC | $541.64 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Astellas Pharma US INC | $473.91 | 2023-2025 | Veozah |
| Pfizer INC. | $453.43 | 2021-2025 | |
| Glaxosmithkline, LLC. | $381.16 | 2022-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Abbvie INC. | $306.31 | 2022-2025 | |
| Abbott Laboratories | $304.18 | 2022-2025 | Freestyle Libre 3 |
| Lilly USA, LLC | $199.38 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Exact Sciences Corporation | $139.55 | 2023-2024 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $121.97 | 2023-2025 | Jardiance, Synjardy, Tradjenta |
| Merck Sharp & Dohme LLC | $87.11 | 2022-2023 | Dificid |
| Bayer Healthcare Pharmaceuticals INC. | $67.39 | 2021-2025 | |
| Corcept Therapeutics | $54.03 | 2023-2025 | Korlym |
| Janssen Pharmaceuticals, INC | $29.74 | 2022-2023 | Xarelto |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $29.44 | 2024-2025 | Caplyta |
| Axsome Therapeutics, INC. | $29.27 | 2025 | Symbravo |
| Sumitomo Pharma America, INC. | $28.95 | 2024 | Gemtesa |
| Daiichi Sankyo INC. | $28.83 | 2024 | Injectafer |
| Lexicon Pharmaceuticals, INC. | $24.26 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $19.73 | 2023 | Trintellix |
| Medtronic, INC. | $18.67 | 2024 | Intellis Adaptivestim |
| Averitas Pharma INC. | $18.15 | 2023 | Qutenza |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $18.04 | 2024 | Xifaxan |
| Esperion Therapeutics, INC. | $16.97 | 2023 | Nexletol |
| Azurity Pharmaceuticals, INC. | $16.25 | 2023 | Edarbi |
| Amgen INC. | $14.84 | 2025 | Repatha, Otezla |
| Boston Scientific Corporation | $14.51 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrea Holzman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.